List of Excipients in Branded Drug DYNA-HEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xttrium Laboratories Inc	DYNA-HEX	chlorhexidine gluconate	0116-1021	CITRIC ACID MONOHYDRATE
Xttrium Laboratories Inc	DYNA-HEX	chlorhexidine gluconate	0116-1021	COCO DIETHANOLAMIDE
Xttrium Laboratories Inc	DYNA-HEX	chlorhexidine gluconate	0116-1021	HYDROXYETHYL CELLULOSE
Xttrium Laboratories Inc	DYNA-HEX	chlorhexidine gluconate	0116-1021	ISOPROPYL ALCOHOL
Xttrium Laboratories Inc	DYNA-HEX	chlorhexidine gluconate	0116-1021	LAURAMINE OXIDE
Xttrium Laboratories Inc	DYNA-HEX	chlorhexidine gluconate	0116-1021	WATER

DYNA-HEX Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

DYNA-HEX is a chlorhexidine gluconate topical antiseptic product family marketed by Dynarex, with products that include 4% chlorhexidine gluconate surgical scrub and lower-concentration chlorhexidine products such as 2% preoperative skin-preparation formats. Its commercial opportunity is driven by formulation performance, skin tolerability, packaging, institutional procurement, and private-label supply rather than by active-ingredient exclusivity.

The strongest excipient strategy is to preserve chlorhexidine’s broad antimicrobial performance while improving foam quality, rinseability, drying time, residue control, skin comfort, packaging compatibility, and product positioning. The principal competitive risks are regulatory classification, hospital purchasing contracts, supply reliability, and substitution by branded chlorhexidine products from BD, Cardinal Health, Medline, and other suppliers.

What is DYNA-HEX and which pharmaceutical products does it include?

DYNA-HEX is a topical antiseptic line based on chlorhexidine gluconate, or CHG. Product formats include liquid skin cleansers, surgical scrubs, and preoperative skin-preparation products. The exact excipient system varies by concentration, dosage form, and intended use.

Product attribute	Commercial relevance
Active ingredient	Chlorhexidine gluconate
Principal use	Healthcare personnel handwash, surgical scrub, patient skin cleansing, and preoperative antisepsis
Typical concentration	2% or 4% CHG, depending on product
Administration	Topical, external use
Primary buyers	Hospitals, ambulatory surgery centers, clinics, long-term-care facilities, distributors
Main competitors	Hibiclens, BD ChloraPrep, Hi-Lyse, Cardinal Health, Medline and private-label products
Regulatory pathway	OTC or healthcare antiseptic framework, depending on product labeling and claims
Exclusivity profile	No meaningful biologic or small-molecule patent exclusivity based on chlorhexidine itself

DYNA-HEX 4 is generally positioned as a 4% chlorhexidine gluconate cleanser or surgical scrub. Products containing isopropyl alcohol and lower CHG concentrations address a different commercial need: rapid drying and preoperative skin preparation.

What excipients are used in DYNA-HEX formulations?

Public product labeling identifies excipient classes used to support cleansing, foaming, skin feel, pH control, color, fragrance, preservation, and manufacturing stability. The precise composition should be evaluated at the individual National Drug Code and product-label level because DYNA-HEX products are not a single formulation.

Common excipient categories include:

Excipient function	Candidate or commonly disclosed component	Formulation purpose
Vehicle	Purified water	Solubilization and delivery
Solvent	Isopropyl alcohol, where included	Rapid drying and enhanced degreasing
Surfactant	Lauramine oxide or related amphoteric/nonionic surfactant	Foam, soil removal, wetting
Solubilizer and stabilizer	Poloxamer	Solubilization, emulsion support, skin feel
Humectant	Glycerin	Reduces drying and improves after-feel
pH adjuster	Sodium hydroxide or acidulant	Controls product pH and CHG stability
Fragrance	Fragrance system, where included	Consumer acceptability
Colorant	Approved cosmetic or drug colorant, where included	Product identification and appearance

Chlorhexidine is cationic. This creates a central excipient constraint: anionic surfactants, anionic polymers, and some negatively charged materials can reduce available CHG through ionic interaction or precipitation. A formulation that performs well as a cleanser may therefore be unsuitable for chlorhexidine delivery unless compatibility is demonstrated.

The highest-value excipient work is not simply replacing one surfactant with another. It requires testing antimicrobial availability, adsorption to containers, compatibility with wipes and nonwoven materials, pH drift, viscosity, foam collapse, rinseability, and residual activity.

Which excipient properties are most important for DYNA-HEX?

Chlorhexidine compatibility

The excipient system must maintain free and available CHG during shelf life and use. Compatibility screening should include:

• Ionic interaction with anionic surfactants and polymers.
• Binding to cellulose, rayon, polyester, polypropylene, and spunlace substrates.
• Adsorption to high-density polyethylene, polypropylene, polyethylene terephthalate, and elastomer closures.
• Precipitation or haze under temperature cycling.
• Active concentration after dilution, pump dispensing, and repeated container opening.

A formulation can retain the labeled CHG concentration while reducing the biologically available fraction. Assay alone is therefore insufficient. Microbiological performance and free-CHG measurements should be part of development.

Skin tolerability

Frequent healthcare use creates demand for lower-irritancy systems. Excipient opportunities include:

• Replacing harsh anionic surfactants with amphoteric or nonionic systems.
• Reducing unnecessary fragrance and colorants.
• Adding humectants at levels that improve skin feel without increasing residue.
• Controlling alcohol concentration to balance drying speed and irritation.
• Optimizing pH for both CHG stability and skin compatibility.

A lower-irritancy formulation may support institutional adoption, especially in intensive-care, neonatal, dialysis, and surgical settings where repeated cleansing is common.

Foam and rinseability

Foam is commercially important for surgical scrub products because it signals coverage and cleaning action. Excessive foam can slow rinsing and create residue. A high-value formulation target is dense initial foam with rapid collapse during rinsing.

Surfactant selection should be evaluated against:

• Foam height and persistence.
• Rinse time.
• Residual film.
• Glove compatibility.
• Skin tightness after repeated use.
• Pump performance at low temperatures.

Drying time

Alcohol-containing products can compete on speed of use. The excipient system must control evaporation without causing excessive flammability, sting, or skin dryness. Opportunities include optimizing alcohol-water ratios, volatile co-solvents, and packaging that limits evaporation during storage.

Packaging compatibility

CHG products are exposed to repeated dispensing and long contact with packaging components. Packaging development should test:

• Active loss to container walls.
• Stress cracking.
• Closure swelling.
• Pump spring and elastomer compatibility.
• Label adhesion after exposure.
• Container opacity and light protection.
• Residual product in pump channels.

Packaging is a practical barrier to rapid copying because a technically acceptable liquid may fail after prolonged contact with the dispenser.

What formulations are protected by DYNA-HEX?

DYNA-HEX products are more likely to be protected by trademarks, regulatory listings, formulation know-how, manufacturing controls, and commercial contracts than by a current composition-of-matter patent covering chlorhexidine.

Chlorhexidine gluconate is an established antiseptic active ingredient. The commercial value of a DYNA-HEX formulation is therefore concentrated in:

1. Excipient ratios and processing conditions.
2. Stability and preservative performance.
3. Foam and skin-feel characteristics.
4. Wipe impregnation and active recovery.
5. Dispenser and container compatibility.
6. Institutional product specifications.
7. Brand recognition and distributor access.

A new entrant would face greater practical risk from confidential know-how, supplier qualification, hospital contracts, and regulatory requirements than from a basic CHG composition patent.

How strong is the DYNA-HEX patent estate?

The apparent patent strength is low for the active ingredient and moderate for formulation-specific improvements.

Asset category	Expected strength
Chlorhexidine composition patent	Low; active is long established
Basic 4% CHG cleanser	Low to moderate
Specialized low-irritancy excipient system	Moderate if supported by comparative data
CHG-impregnated wipe	Moderate, depending on substrate and loading process
Packaging and dispensing system	Moderate
Manufacturing process	Moderate as trade secret; variable as patent asset
Trademark and brand	Commercially important but not patent protection
Hospital contract position	High practical value, non-patent asset

A strong patent filing would require a technically narrow claim supported by comparative evidence. Examples include a defined surfactant system that preserves free CHG, a wipe substrate with improved active recovery, a low-residue formulation with demonstrated antimicrobial equivalence, or a container system that reduces CHG adsorption.

Broad claims covering “chlorhexidine with a surfactant” would face substantial prior-art risk.

What is the FDA regulatory status of DYNA-HEX?

DYNA-HEX is a topical antiseptic product, not a biologic. It does not face biosimilar competition and is not subject to the abbreviated pathway used for biosimilars.

FDA treatment depends on the specific product, concentration, indication, claims, and labeling. The regulatory analysis should distinguish among:

• Healthcare antiseptic handwash products.
• Surgical scrubs.
• Patient preoperative skin preparations.
• Consumer antiseptic washes.
• Alcohol-containing preoperative products.
• CHG-impregnated cloths or wipes.

FDA’s antiseptic rules have treated consumer antiseptic washes and healthcare antiseptics differently. CHG products used in healthcare settings require careful review of the applicable monograph, labeling conditions, safety data, and any product-specific approval status. The product’s Drug Facts label and NDC listing should control the analysis for a particular SKU.[1][2]

What is the Orange Book status of DYNA-HEX?

DYNA-HEX is not generally analyzed as an Orange Book-protected innovator drug in the same manner as an approved NDA product with listed patents. An NDC listing is not equivalent to Orange Book patent listing or FDA approval under an NDA.

The expected regulatory competition is therefore based on compliant OTC or healthcare-antiseptic products, contract manufacturing, private-label supply, and hospital procurement rather than Paragraph IV litigation.

When does DYNA-HEX lose exclusivity?

DYNA-HEX has no identifiable active-ingredient exclusivity period comparable to new chemical entity exclusivity. Chlorhexidine’s commercial use predates modern small-molecule exclusivity frameworks.

The relevant commercial protections are:

Protection	Practical duration
Active-ingredient exclusivity	None of practical significance
Formulation patent	Depends on claim scope and patent term
Trademark	Renewable indefinitely if maintained and used
Trade secret	Potentially indefinite if controlled
Hospital contract	Usually defined by contract term and renewal
Distributor relationship	Depends on channel agreements
Regulatory positioning	Persists while labeling and compliance remain valid

A competing product can generally enter without waiting for an innovator patent expiration if it satisfies the applicable regulatory and labeling requirements. Product differentiation must come from performance, price, supply, packaging, or a defensible formulation claim.

Which companies are challenging or competing with DYNA-HEX?

The competitive field includes branded CHG products, alcohol-based preoperative products, hospital private labels, and alternative antiseptics.

Competitor or category	Competitive basis
Hibiclens	Established CHG brand recognition and retail/healthcare distribution
BD ChloraPrep	Alcohol-based CHG preoperative preparation and applicator system
Medline	Institutional distribution and private-label reach
Cardinal Health	Supply-chain access and healthcare contracting
3M/Solventum antiseptic products	Surgical and hospital procurement position
Povidone-iodine products	Alternative active ingredient and broad procedural use
Alcohol-only preparations	Fast drying and preoperative workflow
Private-label CHG products	Price and contract flexibility

The main commercial distinction is between wash-off CHG cleansers and leave-on preoperative preparations. They should not be treated as interchangeable products in market analysis.

What commercial opportunities exist for DYNA-HEX excipients?

Low-irritancy institutional cleanser

A CHG cleanser with reduced fragrance, lower residue, improved rinseability, and better repeated-use tolerability could target intensive-care units, surgical wards, dialysis centers, and long-term-care facilities.

The value proposition should rely on measured outcomes:

• Lower transepidermal water loss.
• Lower irritation scores.
• Equivalent or superior antimicrobial performance.
• Reduced residue after repeated use.
• Improved user preference.
• Lower product consumption per procedure.

CHG-impregnated wipes

Wipes offer a significant formulation and manufacturing opportunity. The formulation must control CHG loading, uniformity, drying, substrate binding, and active recovery. The major technical risk is loss of available CHG to the nonwoven material.

Potential product segments include:

• Preoperative bathing.
• Intensive-care daily bathing.
• Emergency-department cleansing.
• Ambulance and field-care kits.
• Long-term-care infection-control protocols.

A patentable position may arise from the combination of liquid composition, substrate composition, loading process, packaging atmosphere, and release profile.

Alcohol-CHG rapid-dry systems

A rapidly drying product can compete in operating rooms and procedural settings. Excipient development should focus on reducing sting, controlling flammability risk, preventing leakage, and preserving CHG availability during storage.

Pediatric and sensitive-skin positioning

A formulation with reduced fragrance, lower excipient burden, and stronger tolerability data could support use in populations where repeated antiseptic exposure is commercially important. Claims must remain within the permitted regulatory framework and should not imply unsupported clinical outcomes.

Private-label and contract manufacturing

Dynarex’s product category is suited to private-label expansion because buyers often prioritize:

• Stable supply.
• Consistent specification.
• Multiple package sizes.
• Competitive unit economics.
• Custom labeling.
• Dispenser compatibility.
• Rapid regulatory documentation.

A manufacturer with validated CHG mixing, filling, wipe impregnation, and packaging processes can capture value even without owning a strong patent estate.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are process control and quality consistency. Important controls include:

• CHG assay and content uniformity.
• pH and viscosity.
• Microbial limits.
• Preservative effectiveness where applicable.
• Fill weight and pump delivery.
• Foam performance.
• Stability under accelerated and real-time conditions.
• Container-closure integrity.
• Compatibility with wipes and dispensing systems.

The most defensible intellectual-property strategy combines narrow formulation patents with trade secrets. Patent filings should target measurable technical advantages rather than broad ownership of CHG cleanser concepts.

Useful claim categories include:

• Defined surfactant combinations.
• Free-CHG retention after storage.
• Low-residue or rapid-rinse formulations.
• Specific wipe substrates.
• Active-loading processes.
• Packaging systems that reduce adsorption.
• Dispensing systems that preserve concentration through final dose.

What generic entry risks exist for DYNA-HEX?

Generic entry risk is high because chlorhexidine is an established active ingredient and no conventional new-drug exclusivity barrier controls the category. The risk is moderated by operational factors:

• FDA regulatory requirements.
• Product-specific labeling.
• Hospital qualification procedures.
• Distributor relationships.
• Manufacturing validation.
• Switching costs for dispensers and procedure kits.
• Supply reliability.
• Clinical preference for known brands.

A low-cost liquid cleanser can enter more easily than a validated CHG wipe or integrated applicator. The strongest commercial moat is usually a combination of procurement access, quality history, packaging integration, and documented skin and antimicrobial performance.

What patent litigation and Paragraph IV risks affect DYNA-HEX?

Paragraph IV litigation is not the principal risk for a conventional DYNA-HEX topical antiseptic product without a listed NDA patent estate. The likely disputes are instead:

• Trade-secret misappropriation.
• Contract manufacturing breaches.
• Trademark infringement.
• False or overstated antimicrobial claims.
• Packaging and dispenser patent disputes.
• Private-label supply conflicts.
• Regulatory enforcement related to labeling or manufacturing.

A competitor seeking entry should conduct separate searches of FDA listings, Google Patents, USPTO records, state trademark databases, and federal court dockets for the relevant DYNA-HEX SKU, owner, and formulation.

How does DYNA-HEX compare with Hibiclens and ChloraPrep?

Factor	DYNA-HEX	Hibiclens	ChloraPrep
Core active	CHG	CHG	CHG plus alcohol
Principal format	Cleansers and scrubs	CHG cleanser	Leave-on applicator
Commercial advantage	Price, distribution, product breadth	Brand recognition	Procedure convenience and rapid drying
Main excipient challenge	Foam, residue, skin feel	Tolerability and cleanser performance	Alcohol balance, flammability, packaging
Main IP value	Formulation and brand assets	Brand and product know-how	Applicator, formulation, packaging, and claims
Generic substitution risk	High	Moderate to high	Lower due to integrated delivery system
Best opportunity	Institutional value and private label	Brand extension and sensitive-skin variants	New applicator and delivery formats

Key Takeaways

• DYNA-HEX’s active ingredient does not provide meaningful modern exclusivity.
• Excipient selection is constrained by chlorhexidine’s cationic chemistry.
• The highest-value development areas are low-irritancy cleansing, rapid rinseability, controlled drying, wipe compatibility, and packaging stability.
• CHG-impregnated wipes and integrated applicators offer stronger differentiation than a conventional liquid cleanser.
• Orange Book and Paragraph IV strategies are generally less relevant than regulatory compliance, hospital contracts, trademarks, and manufacturing know-how.
• A defensible patent estate should claim specific excipient ratios, substrate systems, packaging configurations, or measured performance advantages.
• Generic entry risk is high for basic CHG liquids and lower for validated delivery systems with procurement integration.
• The commercial opportunity is strongest in institutional supply, private label, intensive-care bathing, preoperative preparation, and sensitive-skin formulations.

FAQs

Is chlorhexidine gluconate still patent protected?

Chlorhexidine gluconate is an established antiseptic active ingredient without meaningful current composition-of-matter exclusivity. Protection may still apply to specific formulations, delivery systems, packaging, or manufacturing processes.

Can anionic surfactants be used in a DYNA-HEX-type formulation?

They can create compatibility risks because chlorhexidine is cationic. The formulation requires testing for precipitation, active loss, adsorption, antimicrobial performance, and stability before commercial use.

Are DYNA-HEX products eligible for biosimilar competition?

No. DYNA-HEX is a topical small-molecule antiseptic product, not a biologic. Competitive entry would involve a generic, OTC, healthcare-antiseptic, or private-label pathway depending on the product.

What is the best excipient opportunity for a new DYNA-HEX competitor?

A validated low-irritancy CHG formulation, CHG-compatible wipe system, or rapid-drying applicator offers more commercial differentiation than a basic reformulation of 4% CHG cleanser.

Can a CHG formulation support a new patent?

Yes, if it demonstrates a specific and non-obvious technical result. Stronger candidates include improved free-CHG availability, reduced substrate binding, lower residue, enhanced skin tolerability, or improved packaging stability supported by comparative data.

References

1. U.S. Food and Drug Administration. (2016). Safety and effectiveness of consumer antiseptics; topical antimicrobial drug products for over-the-counter human use. Federal Register, 81 Fed. Reg. 61106.

2. U.S. Food and Drug Administration. (2019). Safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the-counter human use. Federal Register, 84 Fed. Reg. 148.

3. U.S. Food and Drug Administration. (n.d.). DailyMed: DYNA-HEX chlorhexidine gluconate topical products. National Library of Medicine.

4. Centers for Disease Control and Prevention. (2017). Guidelines for the prevention of intravascular catheter-related infections. U.S. Department of Health and Human Services.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.